Purpose: This phase I trial investigating the vascular targeting agent NGR-hTNF aimed to determine the (a) dose-limiting toxicities, (b) maximum tolerated dose (MTD), (c) pharmacokinetics and pharmacodynamics, (d) vascular response by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and (e) preliminary clinical activity in solid tumors.
Tumor necrosis factor α (TNFα) is a cytokine well known for its cytostatic and cytotoxic properties, immunomodulatory activities, and selective obstruction and damage of tumor-associated blood vessels. TNFα increases vascular permeability, possibly by disrupting the α v β 3 integrin-mediated endothelial cell adhesion (1) , and kills tumor-associated endothelial cells (2) . It has been suggested that synergy between TNFα and cytotoxic treatment is based on improved drug delivery to tumors due to vascular changes induced by TNFα. A clinical proof of concept was shown in studies of isolated limb perfusion in patients with melanoma and sarcoma (3, 4) . However, systemic administration of TNFα is precluded by severe side effects, especially flu-like symptoms, hemodynamic insufficiency, and hepatic toxicity (5, 6) .
Targeted delivery of TNFα to the tumor could circumvent the toxicity of systemic administration of TNFα. By coupling the tumor-homing peptide CNGRC, a ligand of a CD13 isoform overexpressed by tumor neovasculature, to TNFα (NGR-hTNF), the selective delivery of TNFα to the tumor can be achieved (7) . In murine tumor models, low doses of NGR-hTNF showed greater inhibition of tumor growth compared with untargeted TNFα administered as single agent. It was active either at low doses (0.01-0.1 ng) or at high doses (1,000-10,000 ng), suggesting a bell-shaped dose-response curve. Moreover, low doses of NGR-hTNF enhanced the antitumor activity of chemotherapy, indicating a synergistic effect, without increasing systemic toxicity (8) .
TNFα exerts its effects by binding to two types of receptors, TNF-RI and TNF-RII, which are present on nearly all mammalian cells (9) . After administration of TNFα, a dose-related shedding of soluble TNFα receptors I and II, acting like physiologic attenuators, is observed. In this way, they not only protect the body from harmful effects of TNFα but also limit TNFα bioavailability and antitumor activity.
Efficacy of cytotoxic treatment is typically evaluated by measuring volumetric changes of tumors, according to the Response Evaluation Criteria in Solid Tumors criteria (10) . However, agents targeting the (neo)vasculature may not cause rapid involution of tumors. This is especially relevant because the biological active dose may be considerably lower than the maximum tolerated dose (MTD). Therefore, NGR-hTNF efficacy should be assessed by also evaluating the effect of NGR-hTNF on tumor vasculature.
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive imaging technique that can be used to measure properties of the tumor microvasculature in vivo. Imaging methods sensitive to the presence of the contrast agent in the extravascular extracellular space can provide information on microvessel perfusion, permeability, and extracellular leakage space (11) . DCE-MRI has been introduced previously in phase I studies to assess the pharmacodynamic response to vascular targeting agents (12) (13) (14) (15) (16) (17) (18) .
Here, we present the results from a phase I study, first in human, with i.v. administration of NGR-hTNF. The objectives of this study were (a) to determine the MTD, (b) to characterize the dose-limiting toxicities (DLT), (c) to investigate the pharmacokinetics and pharmacodynamics, (d) to measure the vascular response to NGR-hTNF by DCE-MRI, and (e) to determine preliminary clinical activity.
Patients and Methods
Patient selection. Eligibility criteria included patients ages ≥18 y with histologic or cytologic evidence of advanced cancer not amenable to established forms of effective therapy; Eastern Cooperative Oncology Group performance status ≤2; prior radiotherapy, chemotherapy, or hormonal therapy completed ≥4 wk before study enrollment; life expectancy ≥12 wk; and adequate bone marrow (platelets >100,000/μL, absolute neutrophil count >1,500/μL), hepatic (total bilirubin ≤1.5 × upper limit of normal, and aspartate aminotransferase and alanine aminotransferase <2.5 × upper limit of normal or <5 × upper limit of normal in case of hepatic metastases), and renal (serum creatinine <1.5 × upper limit of normal) functions. All patients gave written informed consent. The study was approved by the medical ethical committee.
Drug administration and study design. This was an openlabel, nonrandomized, multinational phase I dose escalation trial of NGR-hTNF conducted at two sites. NGR-hTNF was provided by MolMed. Before infusion, it was diluted to the appropriate concentration with 0.9% NaCl containing human serum albumin.
NGR-hTNF was administered once every 3 wk by a 20-min i.v. infusion during the four first dose levels and, at dose level 5, by a 1-h i.v. infusion to try to minimize chills during infusion. The starting dose was 0.2 μg/m 2 . The number of dose levels was not fixed in advance. The trial was conducted in two stages: stage 1, accelerated phase and pre-DLT phase; stage 2, DLT stage. The dose escalation process was based on the severity of toxicity observed at each dose level. In stage 1 at the accelerated phase, only one patient per dose level was treated. After observation of grade 2 related toxicity, the pre-DLT phase started with three patients per dose level. As soon as a DLT was observed, the DLT stage started, in which cohorts of six patients were studied. Successive dose levels were defined as DLn = DL(n−1) × 2 (0.4-0.8-1.6… μg/m 2 ) until mild related toxicity (grade <2) and afterward according to a modified Fibonacci. Without affecting the accelerated stage of the first dose levels, two additional patients were entered at the first four dose levels to perform DCE-MRI. In order not to compromise safety, patients 2 and 3 of these dose levels were included only when the patient at the higher dose level had completed cycle 1 of the treatment. After the accelerated phase, dynamic imaging remained optional but at least one to two patients every two dose levels were subject to dynamic imaging.
The incidence and severity of adverse events were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (version 3). Response to therapy was monitored by Response Evaluation Criteria in Solid Tumors. NGR-hTNF-related DLT was assessed at cycle 1 and defined as follows: any grade 3 or 4 nonhematologic toxicity (except for nausea, vomiting, and fever that can be rapidly controlled with appropriate measures), grade 4 neutropenia for ≥7 d, febrile neutropenia, grade 4 thrombocytopenia or thrombocytopenic bleeding requiring transfusion, or severe hypotension requiring dopamine administration. These acute toxicities had to be declared related by the clinical investigator to be taken into account in the decision rule. The MTD was defined as the highest dose at which not more than one DLT was observed among a maximum of six patients. The cohort size at the MTD was expanded to 10 patients.
Pretreatment and follow-up studies. Complete history, physical examination, and routine laboratory studies, including complete blood count, electrolytes, renal and
Translational Relevance
By the use of dynamic contrast-enhanced magnetic resonance imaging, this phase I study shows, for the first time in humans, that treatment with the vascular targeting agent NGR-hTNF causes an antivascular effect in tumors. It also defines the maximum tolerated dose of NGR-hTNF, 45 μg/m 2 , and shows that NGR-hTNF is well tolerated. These findings call for further research for defining the optimal biological dose and clinical activity of NGR-hTNF as a single agent or in combination with cytotoxic drugs.
hepatic functions, urinalysis, electrocardiogram, and tumor assessments, were done pretreatment. During the study, radiologic studies for disease status were repeated after every other cycle. Clinical examination and chemistry were done at the end of each cycle; complete blood counts were done weekly.
Pharmacokinetic sampling, pharmacodynamic determinations, and data analysis. Pharmacokinetic and pharmacodynamic blood sampling was done on day 1 with samples drawn before infusion and at 20, 60, 90, 120, 180, 240, and 360 min after the start of infusion for NGR-hTNF and on day 21. NGR-hTNF antibodies and soluble plasma TNF receptors (sTNF-RI and sTNF-RII) were computed by using an ELISA. Maximum plasma concentration (C max ) and area under the plasma concentration time curve up to the last detectable concentration (AUC 0-t last ) were estimated from plasma concentration time data using standard noncompartmental methods.
DCE-MRI data acquisition and analysis. DCE-MRI was done in patients with either primary or metastatic tumors in the liver or the head and neck region. DCE-MRI data were acquired at baseline, within 1 wk before start of NGR-hTNF, and 2 h after start of the first administration of NGR-hTNF. This 2-h interval was chosen because a maximal synergism between NGR-hTNF and cytotoxic agents has been observed with a 2-h delay between NGR-hTNF and drug administrations, suggesting a maximum effect of NGR-hTNF on the vasculature at that time point (19) .
Measurements were done on a 1.5-T magnetic resonance system (Siemens), using a body phased array coil. After conventional anatomic imaging, 15 mL of 0.5 mol/ L Gd-DOTA (Dotarem) were administered i.v. with an injection rate of 2.5 mL/s by a Spectris magnetic resonance injection system. Using a T1-weighted fast low-angle shot (FLASH) sequence with a time resolution of 2 s, Gd-DOTA uptake in the tumor was monitored and the bolus passage in vessels in the spleen or the carotid artery was monitored. Sequence parameters were repetition time, 50 ms; echo time, 4.4 ms; flip angle, 45°; and slice thickness, 7 mm, four to six slices. DCE-MRI data were acquired for 90 s.
Just before Gd-DOTA injection, proton density-weighted images were recorded with the same sequence parameters as the DCE-MRI except for a flip angle of 8°and a repetition time of 200 ms. Data from these images were combined with the DCE-MRI data to calculate the concentration of Gd-DOTA, using the method described by Hittmair et al. (20) . The tissue relaxivity of Gd-DOTA was assumed to be homogeneously distributed.
For the analysis of the DCE-MRI data, our previously described method was used (21, 22) , with automated detection of a vascular normalization function from pixels in the spleen in case of liver tumors and from pixels in the carotid artery in case of head and neck tumors. The spatial distribution of the values of the rate constant k ep and the volume transfer constant K trans were represented in a map. On a T1-weighted magnetic resonance image, recorded directly before Gd-DOTA arrival in the tumor, regions of interest were drawn, which comprised all tumor tissue in the field of view. These regions of interest were applied to the maps of k ep and K trans to select the single values of k ep and K trans for all tumor pixels. The means of k ep and K trans of the pixels of all slices containing tumor tissue were calculated after log transformation. Log transformation excluded all pixels with values equal to zero, which may be regarded as fitting errors or as necrotic tumor parts. Back transformation of these log-transformed average values resulted in average values of k ep and K trans for the whole tumor (21) . In addition, histograms of the log-transformed pixel values of k ep and K trans were analyzed (23) . For all tumor tissue of each patient, a low threshold value (TV low ) was calculated at baseline from the formula [TV = M − 1.96 × SD] and a high TV from the formula [TV high = M + 1.96 × SD], where M and SD are the mean and the SD values. Then, the numbers of pixels that were below TV low and above TV high were determined for the pharmacokinetic parameters, both at baseline and 2 h after the administration of NGR-hTNF.
Statistical analysis. Safety and efficacy data were summarized using appropriate descriptive statistics. A paired t test was done to assess whether the number of pixels with values of k ep and K trans above and below the predetermined threshold significantly changed after treatment compared with baseline.
Results
General. Seventy patients were included in the study. One patient, on dose level 16, never started treatment due to a gastrointestinal bleeding grade 3 after registration and before start of treatment. This patient was replaced. All baseline characteristics, protocol treatment, and safety sections are described on the safety population (n = 69). Patient characteristics are listed in Table 1 . They received a total of 201 cycles of NGR-hTNF at doses ranging from 0.2 to 60 μg/m 2 . The median number of cycles administered was two (range, 1-12).
In Table 2 , the dose escalation schedule and the DLTs are described. In total, four DLTs were observed, of which three were infusion related. The MTD for NGR-hTNF was 45 μg/m 2 in 1 hour, once per 3 weeks. Adverse events. In Table 3 , all hematologic, biochemical, and nonhematologic adverse events during cycle 1 and over all cycles are summarized. Rigors and fever during infusion were the most frequently observed toxicities. Despite prolonging the duration of the infusion from 20 minutes to 1 hour from dose level 5 (1.95 μg/m 2 ) onward, grade 1 and grade 2 chills did not diminish. Overall, the frequency and the grade of toxicities did not differ between the various dose levels and only mild toxicity was observed.
Pharmacokinetic and pharmacodynamic analyses. Pharmacokinetic analysis was done in all patients. The mean apparent terminal half-life ranged from 0.963 to 2.08 hours. The apparent volume of distribution (V ss ) of NGR-hTNF encompasses total body water, suggesting extensive distribution and/or binding of NGR-hTNF to tissue. Following a 1-hour infusion of NGR-hTNF over the dose range of 0.8 to 60 μg/m 2 NGR-hTNF, the exponent of the power model was 1.30 (95% confidence interval, 1.24-1.36) for C max and 1.26 (95% confidence interval, 1.20-1.31) for AUC 0-4 , indicating a slightly greater than dose-proportional relationship (Fig. 1A and B) .
At low dose (<1.3 μg/m 2 ), the levels of sTNF-RI and sTNF-RII were scattered around zero and thereafter increased proportionally with dose (r 2 = 0.53, P = 0.0014 and r 2 = 0.61, P = 0.0003, respectively), with an apparent plateau observed at ≥25 μg/m 2 ( Fig. 2) . Anti-NGR-hTNF antibodies were not detected.
Antitumor activity. No objective responses were observed. However, 27 patients (39%) showed stable disease with a median duration of 12 weeks and a range between 5 and 35 weeks. Six patients received at least six cycles: one patient on 0.2 μg/m 2 (6 cycles), one patient on 0.8 μg/m 2 (6 cycles), two patients on 1.3 μg/m 2 (6 and 7 cycles), one *Because of one grade 2 toxicity, this dose level was expanded from one to three patients and the pre-DLT phase was started. † One patient never started treatment due to a severe adverse event (gastrointestinal bleeding grade 3) and was replaced. ‡ Three extra patients were entered at a dose of 0.8 μg/m 2 as a 1-h infusion (dose level 18). At this specific dose, DCE-MRI data of the first patient were particularly interesting. Therefore, the cohort of patients at this dose was extended to further examine the "biological effect" of NGR-hTNF at a dose of 0.8 μg/m 2 by DCE-MRI.
patient on 1.95 μg/m 2 (12 cycles), and one on 14.36 μg/ m 2 (6 cycles). DCE-MRI. Thirty-six patients were scheduled to undergo a DCE-MRI. Three did not undergo MRI due to logistical reasons, and in two patients, the acquired data were incomplete. Therefore, in 31 patients, DCE-MRI data were available for analysis. Twenty-six patients had tumors/metastases localized in the liver and five patients had tumors in the head and neck region. The administered dose of NGR-hTNF ranged from 0.2 to 45.0 μg/m 2 according to the predefined protocol.
In 12 patients, a change in k ep in tumor tissue was observed after NGR-hTNF administration, which was larger than the repeatability coefficient that was determined in a previous study (Fig. 3A; ref. 21 ). The repeatability coefficient is a statistical measure, providing direct insight into the probability that differences between two measurements are due to real differences in, for example, tumor biology and not due to the measurement protocol (24) . In selected patients, a decrease in the rate constant k ep in liver metastases after NGR-hTNF could even be observed by visual inspection of the color-coded maps of the spatial distribution of the values of k ep (Fig. 3B and C) . At doses from 1.3 to 25.4 μg/m 2 , the mean k ep and K trans significantly decreased (P < 0.01), whereas at lower and higher dose levels, no statistically significant changes in mean k ep and K trans were observed. On average, in the histogram analysis, the percentage of pixels of k ep and K trans below the lower threshold value significantly increased in all dose levels 2 hours after administration of NGR-hTNF (P < 0.01; Fig.  3D ). The percentage of pixels of k ep and K trans above the higher threshold value did not change significantly (P > 0.1).
There was no relation between pretreatment values of k ep and K trans and the number of cycles of NGR-hTNF that the patients received. In addition, the change in k ep and K trans 2 hours after the administration of NGR-hTNF was not related to the number of cycles of NGR-hTNF that were administered.
Discussion
This is the first report on the systemic treatment of humans with NGR-hTNF. NGR-hTNF is well tolerated, as reflected by the relatively mild side effects even at high dose levels. The most frequently observed toxicities are shortlived rigors, which even occurred despite a more than doubling of the infusion time. Three of four DLTs were infusion-related reactions. Although, theoretically, these chills and infusion-related reactions could have been caused by the NGR peptide, it is more likely that cytokines were induced by the TNFα part of the drug. Preclinical data have shown that the NGR motif is poorly immunogenic, even when it was conjugated to TNF-α or to highly immunogenic carrier proteins (25) . At dose level 17, 60 μg/m 2 in 1 hour, two DLTs were observed during the infusion of NGR-TNF. We did not prolong the infusion time any further as we hypothesized that-assuming a dose-proportional (linear) increase of C max and AUC of NGR-hTNF and a plateau of sTNF receptors at higher dose levelsthe excess of free drug (unbound to circulating receptors) at higher doses would be responsible for systemic toxicities (DLTs). This hypothesis was based on the previous findings using very high doses of TNF in an isolated limb perfusion approach (26) . Therefore, further prolongation of the infusion time was not expected to alter toxicity.
The MTD of NGR-hTNF administered in 1 hour was 45 μg/m 2 once per 3 weeks. It is difficult to compare our results with those obtained with untargeted recombinant TNFα because different administration schedules and infusion times have been applied. Nevertheless, in 19 phase I trials with recombinant TNF, the MTD ranged from 150 to >800 μg/m 2 (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) , which is at least thrice higher than the MTD we found in our study. However, in mice, murine NGR-TNF was 12 to 15 times more effective than murine TNFα with similar toxicity (7) .
The effect of NGR-hTNF on tumor vasculature was assessed by DCE-MRI. In the overall population, the histogram analysis of DCE-MRI data confirmed the antivascular activity of NGR-hTNF. Although results from the histogram analysis, showing activity in all dose levels, are most sensitive to minor changes in the vasculature induced by NGR-TNF, changes in mean values, suggesting a more consistent effect at some dose levels, may also be relevant as a larger number of pixels (i.e., tumor tissue) is involved. Therefore, further DCE-MRI studies on larger and more homogeneous patient populations are highly recommended for dose selection. Ideally, DCE-MRI could be used for dose finding, thus preventing unnecessary exposure of patients to higher dose levels. However, it should be noted that up to now, no biomarker in humans has been proved to adequately reflect the antitumor activity of vascular targeting agents (46) . As is common in a phase I study with a heavily pretreated patient population and a variety of tumor types, no objective responses were observed in our study. Given the fact that direct antivascular effects of NGR-TNF 2 hours after administration were observed by DCE-MRI in this population, it will be useful to incorporate DCE-MRI in a subsequent phase II trial to evaluate its exact role in response prediction.
A confounding variable in the current study is that the magnetic resonance protocol allowed for the assessment of tumor vascularity only at a restricted part of the body (i.e., part of the liver or the head and neck region). Therefore, intrapatient variability of tumor response at other metastatic sites could not be assessed. In addition, DCE-MRI was done only once, at 2 hours after the first dose. This informed us about the direct antivascular effect of NGR-hTNF, but the effect over time of repeated cycles could not be assessed. The lack of correlation between the direct antivascular effect of NGR-hTNF (measured by DCE-MRI) and disease control (measured by the number of administered cycles) suggests that a direct antivascular effect at first cycle is insufficient to predict subsequent treatment outcome. Thus, although the use of DCE-MRI is crucial to obtain a better insight into the biological activity of NGR-hTNF, this method cannot replace the conventional assessment of the MTD. Moreover, the observed nonlinear effect of different doses of NGR-hTNF on tumor vascularity as measured by DCE-MRI underscores the importance of studying the full dose range up to MTD to elucidate the working mechanism of NGR-hTNF (46) .
In conclusion, NGR-hTNF was well tolerated. Its main toxicities are mild-to-moderate rigors and fever. The MTD is 45 μg/m 2 when administered in 1 hour once per 3 weeks. DLTs are mainly infusion related. Although DCE-MRI and pharmacodynamics could not be used to define an exact optimal dose, the antivascular effect observed by DCE-MRI and the increase in levels of sTNF receptors also suggest that doses lower than the MTD are promising and deserve to be explored in further studies with NGR-hTNF, either as a single agent or in combination with cytotoxic drugs. Phase I to II clinical trials are currently ongoing.
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